Skip to main content
Premium Trial:

Request an Annual Quote

Genocea Biosciences Signs CRADA with Naval Medical Research Center for Malaria Vaccine Development


Genocea Biosciences and the Naval Medical Research Center have entered into a cooperative research and development agreement for the identification of antigens to be used in the development of vaccines against malaria.

Under the CRADA, Genocea will apply its proprietary technology to identify novel T-cell antigens from a proteomic screen of Plasmodium falciparum, the parasite that causes malaria in humans. Based on that information, NMRC will develop a candidate vaccine.

The work is being funded with a $2.7 million grant from US Army Medical Research and Material Command to Genocea, based in Cambridge, Mass.

No other terms were disclosed.

In a statement, Staph Leavenworth Bakali, president and CEO of Genocea, said the agreement validates his company's T-cell directed antigen discovery platform technology "and further strengthens our position as a leader in novel vaccine development against pathogens with a high unmet medical need."

According to Genocea's website, the company can "rapidly identify the antigens that result in the in vivo stimulation of protective CD8+ and CD4+ T-cells, targets that can be immediately incorporated into existing antigen delivery systems to produce multivalent vaccine formulations that have the highest probability of generating protective cell-mediated immunity."

Its technology, it added, "essentially" mimics the mammalian immune system in vitro and presents it "with every possible antigen from a disease-causing agent. Genocea can rapidly identify which antigens — out of the entire proteome of a disease target — will best stimulate the immune system in vivo, a task that was not only slow, but previously impossible."

Genocea is also developing a vaccine against Chlamydia trachomatis and against Streptococcus pneumoniae as well as three undisclosed targets.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.